Koninklijke Philips NV ADR (PHG) — Titan Protect Analysis

PHG

Koninklijke Philips NV ADR

Healthcare · ·

$26.11

Data: 2026-06-03

✓ ETHICAL PASS

NARROW MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$24.7B

Total market value of the company

Trailing P/E

21.88

Premium valuation

Forward P/E

12.44

Based on estimated future earnings — lower means cheaper

Rev Growth

-4.7%

Year-over-year revenue change

Profit Margin

5.5%

How much profit the company keeps from each dollar of revenue

ROE

8.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$31.00

+19% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 5 analysts covering this stock

About Koninklijke Philips NV ADR

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. The company provides diagnostic imaging solutions, includes ultrasound business unit, magnetic resonance imaging, computed tomography, and diagnostic x-ray; Image Guided Therapy, including image guided therapy systems and image guided therapy devices. It also offers monitoring, enterpris

https://www.philips.com

Country: Netherlands Employees: 64,317 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.256

Positive but modest risk-adjusted returns

Kelly Fraction

0.0104

Marginal edge — very small allocation suggested

Calmar Ratio

0.088

Drawdown risk outweighs the returns — higher risk profile

Annual Return

3.0%

Historical annualised return based on price data

Max Drawdown

-33.8%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.92

Less volatile than the market — more defensive

52W High

$33.44

22% below the year high

52W Low

$21.95

19% above the year low

Avg Volume

1,144,376

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

398.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$1.16

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

70.91

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

45.2%

Revenue left after cost of goods — higher means pricing power

Operating Margin

6.2%

Profit from core operations before interest and tax

Free Cash Flow

$1.5B

Positive — the business generates more cash than it spends

Revenue (TTM)

$17.6B

Total revenue over the last 12 months

Net Income

$968M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$41.00

Target Median

$31.00

Target Low

$29.20

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go